Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Short-term Investments (2016 - 2017)

Crescent Biopharma (CBIO) has disclosed Short-term Investments for 5 consecutive years, with $5219.0 as the latest value for Q1 2017.

  • For Q1 2017, Short-term Investments fell 24.46% year-over-year to $5219.0; the TTM value through Mar 2017 reached $5219.0, down 24.46%, while the annual FY2016 figure was $10649.0, 14.88% up from the prior year.
  • Short-term Investments hit $5219.0 in Q1 2017 for Crescent Biopharma, down from $10649.0 in the prior quarter.
  • Across five years, Short-term Investments topped out at $16293.0 in Q4 2014 and bottomed at $1000.0 in Q4 2013.
  • Average Short-term Investments over 5 years is $8766.7, with a median of $9948.0 recorded in 2015.
  • Year-over-year, Short-term Investments soared 1529.3% in 2014 and then tumbled 92.17% in 2016.
  • Crescent Biopharma's Short-term Investments stood at $1000.0 in 2013, then skyrocketed by 1529.3% to $16293.0 in 2014, then tumbled by 43.1% to $9270.0 in 2015, then grew by 14.88% to $10649.0 in 2016, then crashed by 50.99% to $5219.0 in 2017.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $5219.0, $10649.0, and $1000.0 for Q1 2017, Q4 2016, and Q2 2016 respectively.